This company has been marked as potentially delisted and may not be actively trading. Cytori Therapeutics (CYTX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CYTX vs. CRIS, SABS, BOLT, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIBShould you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include Curis (CRIS), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. Cytori Therapeutics vs. Curis SAB Biotherapeutics Bolt Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Cytori Therapeutics (NASDAQ:CYTX) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability. Do analysts rate CYTX or CRIS? Curis has a consensus target price of $17.00, indicating a potential upside of 750.00%. Given Curis' stronger consensus rating and higher possible upside, analysts clearly believe Curis is more favorable than Cytori Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytori Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Curis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, CYTX or CRIS? Cytori Therapeutics has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.65, suggesting that its stock price is 265% more volatile than the S&P 500. Is CYTX or CRIS more profitable? Cytori Therapeutics has a net margin of -242.60% compared to Curis' net margin of -443.35%. Cytori Therapeutics' return on equity of -272.70% beat Curis' return on equity.Company Net Margins Return on Equity Return on Assets Cytori Therapeutics-242.60% -272.70% -56.23% Curis -443.35%-923.37%-78.35% Which has preferable valuation and earnings, CYTX or CRIS? Cytori Therapeutics has higher earnings, but lower revenue than Curis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytori Therapeutics$3.67M1.89-$12.63MN/AN/ACuris$11.20M1.87-$47.41M-$6.23-0.32 Do insiders & institutionals have more ownership in CYTX or CRIS? 2.6% of Cytori Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 0.7% of Cytori Therapeutics shares are held by insiders. Comparatively, 5.7% of Curis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in CYTX or CRIS? Curis received 253 more outperform votes than Cytori Therapeutics when rated by MarketBeat users. However, 73.67% of users gave Cytori Therapeutics an outperform vote while only 67.28% of users gave Curis an outperform vote. CompanyUnderperformOutperformCytori TherapeuticsOutperform Votes44273.67% Underperform Votes15826.33% CurisOutperform Votes69567.28% Underperform Votes33832.72% Does the media prefer CYTX or CRIS? In the previous week, Curis had 6 more articles in the media than Cytori Therapeutics. MarketBeat recorded 6 mentions for Curis and 0 mentions for Cytori Therapeutics. Curis' average media sentiment score of 0.62 beat Cytori Therapeutics' score of 0.00 indicating that Curis is being referred to more favorably in the news media. Company Overall Sentiment Cytori Therapeutics Neutral Curis Positive SummaryCuris beats Cytori Therapeutics on 10 of the 16 factors compared between the two stocks. Get Cytori Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTX vs. The Competition Export to ExcelMetricCytori TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.94M$4.38B$5.33B$8.31BDividend YieldN/A43.63%5.20%4.10%P/E RatioN/A29.0626.7219.60Price / Sales1.8973.00395.56117.92Price / CashN/A51.0838.3234.62Price / Book0.896.186.764.50Net Income-$12.63M$66.96M$3.23B$248.40M Cytori Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTXCytori TherapeuticsN/A$0.31-7.7%N/A-84.1%$6.94M$3.67M0.0037Gap DownHigh Trading VolumeCRISCuris3.054 of 5 stars$2.12+1.9%$17.00+701.9%-81.6%$22.18M$11.20M-0.2760Analyst RevisionSABSSAB Biotherapeutics2.854 of 5 stars$1.84+2.4%$12.20+562.1%-32.9%$17.12M$2.24M-0.50140BOLTBolt Biotherapeutics3.2477 of 5 stars$0.33+0.6%$2.50+658.3%-57.5%$12.64M$7.69M-0.1990Analyst ForecastGap DownMTEMMolecular TemplatesN/AN/AN/AN/A$1,000.00$23.48M0.00260AMGNAmgen4.3664 of 5 stars$275.01-0.3%$309.22+12.4%-12.1%$147.87B$34.13B36.4325,200Positive NewsAnalyst ForecastAnalyst RevisionGILDGilead Sciences4.6331 of 5 stars$109.11+2.8%$110.55+1.3%+57.4%$135.73B$28.74B294.8917,000Positive NewsAnalyst ForecastInsider TradeOptions VolumeVRTXVertex Pharmaceuticals4.6064 of 5 stars$447.18+1.5%$515.04+15.2%-3.0%$114.83B$11.10B-203.264,800Positive NewsREGNRegeneron Pharmaceuticals4.7857 of 5 stars$614.79+3.2%$890.60+44.9%-39.3%$66.38B$14.09B16.0611,900Positive NewsDividend AnnouncementEx-DividendALNYAlnylam Pharmaceuticals4.1663 of 5 stars$291.68-0.1%$319.17+9.4%+91.5%$38.03B$2.35B-134.412,000Positive NewsBIIBBiogen4.8959 of 5 stars$130.55+0.9%$191.30+46.5%-43.9%$19.13B$9.82B11.678,720Positive News Related Companies and Tools Related Companies CRIS Competitors SABS Competitors BOLT Competitors MTEM Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTX) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytori Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYTX Stock Free CYTX Stock Alerts